21 |
O'6-alkylguanine adducts : detection and biological significanceAllinson, Sarah L. January 1998 (has links)
No description available.
|
22 |
Antibody response to a pneumococcal polysaccharide vaccine in humans : clinical study on the use of such vaccine to test for immunodeficiencyLatif, Ammar A. A. January 1982 (has links)
No description available.
|
23 |
Radiolabelled antibody imaging : Monitoring the localisation of tumor associated monoclonal antibodies by gamma scintigraphyPerkins, A. C. January 1985 (has links)
No description available.
|
24 |
Studies on genetically engineered antibodiesRoberts, S. January 1987 (has links)
No description available.
|
25 |
Studies on the production of human monoclonal antibodiesBell, Graham Thomas January 1988 (has links)
No description available.
|
26 |
Engineering recombinant antibodies for immunosensors: Incorporating peptide tags for gold nanoparticle binding and incorporating the 12F6 antibody in a lateral flow device for detection of uranium in groundwaterJanuary 2018 (has links)
archives@tulane.edu / Groundwater contamination due to the presence of uranium is a subject of concern since chronic exposure to uranium can lead to health problems such as renal failure and cancer. Current standard methods for detection and quantification of uranium in groundwater require expensive instrumentation, laborious sample preparation processes and highly skilled labor to perform. Simple, portable immunosensors can reduce analysis times and costs. Immunosensors take advantage the ability of antibodies to recognize specific molecules. The antibody-antigen binding event can then be read using a quantifiable signal such as color. The success of immunosensors largely depends on the quality of the antibody.
In this report, a single chain variable fragment antibody (scFv) was generated from the monoclonal antibody, 12F6 to be used for further studies and re-engineering. The 12F6 antibody binds hexavalent uranium complexed to the chelator, 2,9-dicarboxyl-1,10-phenanthroline (DCP). This scFv was re-engineered in attempt to improve stability as well as adjust it for possible application in a lateral flow device.
The full length 12F6 was used to develop a paper-based lateral flow immunoassay device for the detection of uranium in groundwater. Gold nanoparticles were conjugated to the 12F6 antibody to be used as a label. Gold nanoparticles were chosen as a label for this immunoassay due to their biocompatibility and intense plasmonic effect. These immunosensors can be used for rapid testing of groundwater at sites of contamination. This assay could quantify uranium at concentrations below the maximum contaminant level (MCL) for drinking water, 30ppb, or 126nM, as stipulated by the U.S. Environmental Protection Agency (EPA) and the World Health Organization (WHO). / 1 / Grace A. Jairo
|
27 |
Monoclonal antibodies specific to the putative cancer signaling protein, Uev1APelzer, Lindsay Jolene 31 January 2008
UEV1A and MMS2 are two human genes whose proteins share greater than ninety percent sequence identity. Both Uev1A and Mms2 are ubiquitin-conjugating enzyme variants (Uev) that lack the active cystine residue required for the ubiquitin conjugation reaction. They work with the ubiquitin-conjugating enzyme Ubc13 to create Lys63-linked polyubiquitin chains which have recently been found to cause cellular signals not involving target protein degradation. Only the Mms2-Ubc13 complex functions in DNA repair in mammalian cells. In contrast, only the Uev1A-Ubc13 complex is involved in TRAF2- and TRAF6-mediated NF-¦ÊB activation by ubiquitinating NEMO/IKKg. UEV1B is a splice variant of UEV1A containing different N-terminal coding sequences and its cellular function is currently unknown. <p>The NF-¦ÊB signaling pathway has been regarded as a primary pro-survival and anti-apoptotic response. UEV1A expression is positively correlated to tumor formation, suggesting that it plays a role in tumorigenesis. Furthermore, experimental overexpression of UEV1A alone is sufficient to activate NF-¦ÊB, which is reversible upon suppression of UEV1A expression by RNA interference. Overexpression of UEV1A also protects cells from stress-induced apoptosis and confers a growth advantage under serum-deprived conditions. These observations collectively support UEV1A as a candidate proto-oncogene.<p> The objective of this research was to obtain monoclonal antibodies (Mabs) capable of recognizing Uev1, but not Mms2. This is a challenging task given very few possible epitopes that may distinguish the two proteins. The four sequences unique to Uev1A are located in the 30 a.a. N terminal region, the single substitution at a.a. 104, the 14 a.a. core region from a.a. 116-129 (7/14 variable) and the C-terminus at a.a. 167-169.<p>Hybridoma cells were produced vis ¨¢ vis fusions of B cells from Uev1A-immunized mice with FO myeloma cells lacking the ability to produce immunoglobulin. The hybridoma cells were screened using enzyme immunoassays (EIAs) for reactivity with Uev1A and Mms2. Ascities fluid was produced for five Mabs named LN1, LN2, LN2A, LN2B and LN3. EIA and Western blotting of Uev1A-deletion constructs revealed that Mab LN1 binds specifically to amino acids (a.a.) 10-30 of the unique Uev1A N-terminal sequence, that Mabs LN2, LN2A and LN2B bind specifically to the unique a.a. 110-130 region of Uev1A, and that Mab LN3 binds specifically to a.a. 30-44 of Uev1A common to Mms2.<p> Competition analysis of unconjugated Mabs versus horse radish peroxidase (HRP)-conjugated Mabs for binding to Uev1A permitted epitope mapping for the five Mabs. The results indicate that Mabs LN1 and LN3 inhibit each other from binding to their distinct sequences which are spatially adjacent. Mabs LN2 and LN2B inhibit each other, but not Mab LN2A. Additionally, Mab LN2A is unable to inhibit Mabs LN2 or LN2B. In summary, Mabs have been aquired to three catergories which were originally desired: one to the unique N-terminus (Mab LN1), three to the unique core sequence (Mabs LN2, LN2B and LN2A), and one to the same region Ubc13 binds to Uev1A and Mms2 (Mab LN3). The potential applications of these Mabs are discussed.
|
28 |
Monoclonal antibodies specific to the putative cancer signaling protein, Uev1APelzer, Lindsay Jolene 31 January 2008 (has links)
UEV1A and MMS2 are two human genes whose proteins share greater than ninety percent sequence identity. Both Uev1A and Mms2 are ubiquitin-conjugating enzyme variants (Uev) that lack the active cystine residue required for the ubiquitin conjugation reaction. They work with the ubiquitin-conjugating enzyme Ubc13 to create Lys63-linked polyubiquitin chains which have recently been found to cause cellular signals not involving target protein degradation. Only the Mms2-Ubc13 complex functions in DNA repair in mammalian cells. In contrast, only the Uev1A-Ubc13 complex is involved in TRAF2- and TRAF6-mediated NF-¦ÊB activation by ubiquitinating NEMO/IKKg. UEV1B is a splice variant of UEV1A containing different N-terminal coding sequences and its cellular function is currently unknown. <p>The NF-¦ÊB signaling pathway has been regarded as a primary pro-survival and anti-apoptotic response. UEV1A expression is positively correlated to tumor formation, suggesting that it plays a role in tumorigenesis. Furthermore, experimental overexpression of UEV1A alone is sufficient to activate NF-¦ÊB, which is reversible upon suppression of UEV1A expression by RNA interference. Overexpression of UEV1A also protects cells from stress-induced apoptosis and confers a growth advantage under serum-deprived conditions. These observations collectively support UEV1A as a candidate proto-oncogene.<p> The objective of this research was to obtain monoclonal antibodies (Mabs) capable of recognizing Uev1, but not Mms2. This is a challenging task given very few possible epitopes that may distinguish the two proteins. The four sequences unique to Uev1A are located in the 30 a.a. N terminal region, the single substitution at a.a. 104, the 14 a.a. core region from a.a. 116-129 (7/14 variable) and the C-terminus at a.a. 167-169.<p>Hybridoma cells were produced vis ¨¢ vis fusions of B cells from Uev1A-immunized mice with FO myeloma cells lacking the ability to produce immunoglobulin. The hybridoma cells were screened using enzyme immunoassays (EIAs) for reactivity with Uev1A and Mms2. Ascities fluid was produced for five Mabs named LN1, LN2, LN2A, LN2B and LN3. EIA and Western blotting of Uev1A-deletion constructs revealed that Mab LN1 binds specifically to amino acids (a.a.) 10-30 of the unique Uev1A N-terminal sequence, that Mabs LN2, LN2A and LN2B bind specifically to the unique a.a. 110-130 region of Uev1A, and that Mab LN3 binds specifically to a.a. 30-44 of Uev1A common to Mms2.<p> Competition analysis of unconjugated Mabs versus horse radish peroxidase (HRP)-conjugated Mabs for binding to Uev1A permitted epitope mapping for the five Mabs. The results indicate that Mabs LN1 and LN3 inhibit each other from binding to their distinct sequences which are spatially adjacent. Mabs LN2 and LN2B inhibit each other, but not Mab LN2A. Additionally, Mab LN2A is unable to inhibit Mabs LN2 or LN2B. In summary, Mabs have been aquired to three catergories which were originally desired: one to the unique N-terminus (Mab LN1), three to the unique core sequence (Mabs LN2, LN2B and LN2A), and one to the same region Ubc13 binds to Uev1A and Mms2 (Mab LN3). The potential applications of these Mabs are discussed.
|
29 |
An investigation of the nutrient gradients in aggregates of animal cells in cultureAnuar, Nurina January 1998 (has links)
No description available.
|
30 |
The rapid detection of salmonella by an IMS-ELISA systemMansfield, Lucielle Pauline January 1999 (has links)
No description available.
|
Page generated in 0.0259 seconds